Mayo Clinic Department of Immunology, Rochester, MN, USA.
Mayo Clinic Department of Molecular Medicine, Rochester, MN, USA.
Brain. 2020 Dec 1;143(12):3629-3652. doi: 10.1093/brain/awaa343.
Immunosuppression of unknown aetiology is a hallmark feature of glioblastoma and is characterized by decreased CD4 T-cell counts and downregulation of major histocompatibility complex class II expression on peripheral blood monocytes in patients. This immunosuppression is a critical barrier to the successful development of immunotherapies for glioblastoma. We recapitulated the immunosuppression observed in glioblastoma patients in the C57BL/6 mouse and investigated the aetiology of low CD4 T-cell counts. We determined that thymic involution was a hallmark feature of immunosuppression in three distinct models of brain cancer, including mice harbouring GL261 glioma, B16 melanoma, and in a spontaneous model of diffuse intrinsic pontine glioma. In addition to thymic involution, we determined that tumour growth in the brain induced significant splenic involution, reductions in peripheral T cells, reduced MHC II expression on blood leucocytes, and a modest increase in bone marrow resident CD4 T cells. Using parabiosis we report that thymic involution, declines in peripheral T-cell counts, and reduced major histocompatibility complex class II expression levels were mediated through circulating blood-derived factors. Conversely, T-cell sequestration in the bone marrow was not governed through circulating factors. Serum isolated from glioma-bearing mice potently inhibited proliferation and functions of T cells both in vitro and in vivo. Interestingly, the factor responsible for immunosuppression in serum is non-steroidal and of high molecular weight. Through further analysis of neurological disease models, we determined that the immunosuppression was not unique to cancer itself, but rather occurs in response to brain injury. Non-cancerous acute neurological insults also induced significant thymic involution and rendered serum immunosuppressive. Both thymic involution and serum-derived immunosuppression were reversible upon clearance of brain insults. These findings demonstrate that brain cancers cause multifaceted immunosuppression and pinpoint circulating factors as a target of intervention to restore immunity.
病因不明的免疫抑制是胶质母细胞瘤的一个显著特征,其特点是患者外周血单核细胞中的 CD4 T 细胞计数减少和主要组织相容性复合体 II 表达下调。这种免疫抑制是胶质母细胞瘤免疫疗法成功发展的一个关键障碍。我们在 C57BL/6 小鼠中重现了胶质母细胞瘤患者中观察到的免疫抑制,并研究了 CD4 T 细胞计数降低的病因。我们确定,胸腺萎缩是三种不同脑癌模型(包括携带 GL261 神经胶质瘤的小鼠、B16 黑色素瘤和弥漫性内在脑桥神经胶质瘤的自发模型)中免疫抑制的一个显著特征。除了胸腺萎缩,我们还确定,大脑中的肿瘤生长导致脾脏严重萎缩,外周 T 细胞减少,血液白细胞上 MHC II 表达降低,骨髓中常驻 CD4 T 细胞略有增加。通过联体实验,我们报告胸腺萎缩、外周 T 细胞计数下降和 MHC II 表达水平降低是通过循环血液衍生因子介导的。相反,骨髓中的 T 细胞隔离不受循环因子控制。来自携带神经胶质瘤小鼠的血清可强烈抑制体外和体内 T 细胞的增殖和功能。有趣的是,导致血清免疫抑制的因子是非甾体类和高分子量的。通过对神经疾病模型的进一步分析,我们确定免疫抑制不仅是癌症本身所特有的,而且是对脑损伤的反应。非癌症性急性神经损伤也会导致显著的胸腺萎缩,并使血清具有免疫抑制作用。在清除脑损伤后,胸腺萎缩和血清来源的免疫抑制都是可逆的。这些发现表明脑癌会引起多方面的免疫抑制,并指出循环因子是恢复免疫的干预目标。